Navigation Links
Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology
Date:5/22/2009

WAYNE, N.J., May 22 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc. today announced that new data on Bayer's novel anti-cancer development candidate BAY 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, May 29 - June 2.

"Bayer is committed to expanding our oncology franchise, and the oral multi-kinase inhibitor BAY 73-4506 is one of the promising compounds in the company's pipeline," said Kemal Malik, MD, member of the Board of Management and Chief Medical Officer and Head of Global Development at Bayer HealthCare. "We look forward to determining the role of BAY 73-4506, along with other compounds in our franchise, in creating potential treatment options for patients afflicted with various cancers."

The BAY 73-4506 data being presented are:

BAY 73-4506

  • Phase I study of BAY 73-4506, an inhibitor of oncogenic and angiogenic kinases, in patients with advanced refractory colorectal carcinoma
    • Dirk Strumberg, MD, Department of Hematology and Medical Oncology, Marienhospital Herne, University Medical School of Bochum, Germany
    • Abstract 3560, Poster, Saturday, May 30, 2009, 8:00-11:00 a.m., Level 2, West Hall C

  • Phase II study of BAY 73-4506, a multikinase inhibitor, in previously untreated patients with metastatic or unresectable renal cell cancer
    • Professor Tim Eisen, PhD, Addenbrooke's Hospital and the University of Cambridge, UK
    • Abstract 5033, Poster Discussion, Friday, May 29, 2009, 2:00-6:00 p.m., Level 2, W230A

About BAY 73-4506 (DAST-Inhibitor)

BAY 73-4506 is a novel oral multi-kinase inhibitor with a kinase inhibition profile targeting angiogenic, stromal and oncogenic receptor tyrosine kinases (TK). BAY 73-4506 has been shown to inhibit tumor growth in preclinical models by hitting targets along a spectrum of angiogenic pathways, including VEGFR and TIE2. BAY 73-4506 has also been shown to prevent the proliferation of tumor cell lines while promoting apoptosis (cell death) by directly targeting several oncogenic TK receptors. The mechanism may offer promise to treat a broad spectrum of tumors.

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceuticals Inc. is the U.S.-based pharmaceuticals unit of Bayer HealthCare LLC, a subsidiary of Bayer Corporation. One of the world's leading, innovative companies in the healthcare and medical products industry, Bayer HealthCare combines the global activities of the Animal Health, Consumer Care, Diabetes Care, and Pharmaceuticals divisions. In the U.S., Bayer HealthCare Pharmaceuticals comprises the following business units: Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare. The company's aim is to provide products that will improve human health worldwide by diagnosing, preventing and treating diseases.

Details on the studies can be found on the ASCO website: www.abstract.asco.org.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.


'/>"/>
SOURCE Bayer HealthCare Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Now Available: Bayer Diabetes Cares CONTOUR(R) Meters in Midnight Blue and Orange Burst
2. Bayer CropScience Welcomes New Emergency Services Leader to the Institute Site
3. J&J, Schering-Plough, Novartis, Bayer vie for Top Honors at the Premier OTC / Healthcare Ad Awards
4. Bayer HealthCare Marks 20th Anniversary of World Hemophilia Day With Euro 250,000 Contribution to the World Federation of Hemophilia
5. Nick Jonas and Bayer Diabetes Care Launch Creativity Contest to Encourage Kids With Diabetes to Express Their Simple Win
6. Bayer Awards $200,000 to National Science Teachers Association to Nurture Early-Career Science Teachers
7. Bayer Consumer Care Joins Forces with WomenHeart to Fight Heart Disease
8. Podcast from Medialink, Bayer Healthcare LLC and WomenHeart: WomenHeart - Strong @Heart
9. Bayer Healthcare and WomenHeart Launch Strong @Heart Campaign
10. Bayer Healthcare to Pay U.S. $97.5 Million to Settle Allegations of Paying Kickbacks to Diabetic Suppliers
11. Bayer HealthCare Donates Hundreds of Food Items to Community Food Bank of New Jersey in Response to Governors Plea to Help the States Population in Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Florida’s philanthropic community at its 10th anniversary Fashion Luncheon on Monday, February 8, ...
(Date:2/12/2016)... ... 2016 , ... As a former television executive, owner Tal Rabinowitz knows how ... to decompress, Rabinowitz found herself drawn to a casual meditation class while working at ... life, implementing a 20-minute-per-day meditation practice with her team. After her tenure at NBC, ...
(Date:2/12/2016)... ... 12, 2016 , ... Itopia, a leader in cloud services ... Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. This ... small and medium business (SMB) clients. , In recent years, BI ...
(Date:2/12/2016)... Arlington, TX (PRWEB) , ... February 12, 2016 , ... ... Worth, and other communities across eastern Texas, is launching a cooperative charity drive with ... and families. , Serving more than 50,000 individuals and families in need, the Tarrant ...
(Date:2/12/2016)... ... ... Donor Network West, the organ procurement organization that heals lives through organ ... Regional Medical Center. Under the collaboration, the first of its kind, specific organ donors ... certain time frame for donor families for the recovery of organs. , Organ ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... -- Eli Lilly and Company (NYSE: LLY ) today announced ... vitamin regimen patent would not presently be infringed by Actavis ... , Italy and Spain ... dextrose solution.  --> --> ... held that Lilly,s patent would be indirectly infringed by Actavis ...
(Date:2/12/2016)... 2016  Apellis Pharmaceuticals, Inc., today announced ... Series D preferred stock financing, co-led by ... Group and venBio Global Strategic Fund, joining ... Investment, and Epidarex Capital. The proceeds of the ... clinical trials in the Company,s ongoing complement ...
(Date:2/11/2016)... , Feb. 11, 2016 The primary ... and future adoption patterns on the usage of liquid ... the following: - Timeframe of liquid biopsy ... ctDNA, cfDNA and Evs—by organization type - Sample inflow ... types: blood, saliva, stool, serum, and so on. - ...
Breaking Medicine Technology: